• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微创与开放根治性切除术治疗肝门部胆管癌:微创优势与可比结局相关。

Minimally invasive versus open radical resection surgery for hilar cholangiocarcinoma: Comparable outcomes associated with advantages of minimal invasiveness.

机构信息

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

出版信息

PLoS One. 2021 Mar 11;16(3):e0248534. doi: 10.1371/journal.pone.0248534. eCollection 2021.

DOI:10.1371/journal.pone.0248534
PMID:33705481
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7951922/
Abstract

BACKGROUND

Minimally invasive surgery (MIS) provides a new approach for patients with hilar cholangiocarcinoma (HCCA). However, whether it can achieve similar outcomes to traditional open surgery (OS) remains controversial.

METHODS

To assess the safety and feasibility of MIS for HCCA, a systematic review and meta-analysis was performed to compare the outcomes of MIS with OS. Seventeen outcomes were assessed.

RESULTS

Nine studies involving 382 patients were included. MIS was comparable in blood transfusion rate, R0 resection rate, lymph nodes received, overall morbidity, severe morbidity (Clavien-Dindo classification > = 3), bile leakage rate, wound infection rate, intra-abdominal infection rate, days until oral feeding, 1-year overall survival, 2-year overall survival and postoperative mortality with OS. Although operation time was longer (mean difference (MD) = 93.51, 95% confidence interval (CI) = 64.10 to 122.91, P < 0.00001) and hospital cost (MD = 0.68, 95% CI = 0.03 to 1.33, P = 0.04) was higher in MIS, MIS was associated with advantages of minimal invasiveness, that was less blood loss (MD = -81.85, 95% CI = -92.09 to -71.62, P < 0.00001), less postoperative pain (MD = -1.21, 95% CI = -1.63 to -0.79, P < 0.00001), and shorter hospital stay (MD = -4.22, 95% CI = -5.65 to -2.80, P < 0.00001).

CONCLUSIONS

The safety and feasibility of MIS for HCCA is acceptable in selected patients. MIS is a remarkable alternative to OS for providing comparable outcomes associated with a benefit of minimal invasiveness and its application should be considered more.

摘要

背景

微创外科(MIS)为肝门部胆管癌(HCCA)患者提供了一种新的治疗方法。然而,它是否能达到与传统开腹手术(OS)相同的效果仍存在争议。

方法

为了评估 MIS 治疗 HCCA 的安全性和可行性,我们进行了一项系统评价和荟萃分析,比较了 MIS 与 OS 的治疗效果。评估了 17 项结果。

结果

纳入了 9 项研究共 382 例患者。MIS 在输血率、R0 切除率、淋巴结清扫数、总并发症发生率、严重并发症发生率(Clavien-Dindo 分级≥3)、胆漏发生率、切口感染率、腹腔感染率、开始口服饮食时间、1 年总生存率、2 年总生存率和术后死亡率方面与 OS 相当。尽管 MIS 的手术时间较长(均数差(MD)=93.51,95%置信区间(CI)=64.10 至 122.91,P<0.00001),且住院费用较高(MD=0.68,95%CI=0.03 至 1.33,P=0.04),但 MIS 具有微创优势,术中出血量更少(MD=-81.85,95%CI=-92.09 至-71.62,P<0.00001),术后疼痛较轻(MD=-1.21,95%CI=-1.63 至-0.79,P<0.00001),住院时间较短(MD=-4.22,95%CI=-5.65 至-2.80,P<0.00001)。

结论

在选择合适的患者中,MIS 治疗 HCCA 的安全性和可行性是可以接受的。MIS 是 OS 的一种显著替代方法,可提供相似的结果,并具有微创优势,应更多地考虑应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/a0575c274fc2/pone.0248534.g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/9e75b0f6059b/pone.0248534.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/14d0d973f6ff/pone.0248534.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/317c4a9b0434/pone.0248534.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/73aea5d47923/pone.0248534.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/9d7ba0797a2b/pone.0248534.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/d5dce86608e4/pone.0248534.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/57e2b388137d/pone.0248534.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/d93be25f324a/pone.0248534.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/fa49c6860e53/pone.0248534.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/47b3ea405484/pone.0248534.g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/8f22d9d50876/pone.0248534.g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/c64eae932b35/pone.0248534.g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/3e7ad4b35ab6/pone.0248534.g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/19241ab93f76/pone.0248534.g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/c542e72cb62c/pone.0248534.g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/6df898729d10/pone.0248534.g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/1acba0f7635b/pone.0248534.g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/a0575c274fc2/pone.0248534.g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/9e75b0f6059b/pone.0248534.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/14d0d973f6ff/pone.0248534.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/317c4a9b0434/pone.0248534.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/73aea5d47923/pone.0248534.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/9d7ba0797a2b/pone.0248534.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/d5dce86608e4/pone.0248534.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/57e2b388137d/pone.0248534.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/d93be25f324a/pone.0248534.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/fa49c6860e53/pone.0248534.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/47b3ea405484/pone.0248534.g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/8f22d9d50876/pone.0248534.g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/c64eae932b35/pone.0248534.g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/3e7ad4b35ab6/pone.0248534.g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/19241ab93f76/pone.0248534.g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/c542e72cb62c/pone.0248534.g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/6df898729d10/pone.0248534.g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/1acba0f7635b/pone.0248534.g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecda/7951922/a0575c274fc2/pone.0248534.g018.jpg

相似文献

1
Minimally invasive versus open radical resection surgery for hilar cholangiocarcinoma: Comparable outcomes associated with advantages of minimal invasiveness.微创与开放根治性切除术治疗肝门部胆管癌:微创优势与可比结局相关。
PLoS One. 2021 Mar 11;16(3):e0248534. doi: 10.1371/journal.pone.0248534. eCollection 2021.
2
[Robotic hilar cholangiocarcinoma radical resection compared with laparotomy in prognosis].机器人肝门部胆管癌根治性切除术与开腹手术预后的比较
Zhonghua Wai Ke Za Zhi. 2020 Mar 1;58(3):230-234. doi: 10.3760/cma.j.issn.0529-5815.2020.03.012.
3
Total laparoscopic versus open radical resection for hilar cholangiocarcinoma.全腹腔镜与开腹根治性切除术治疗肝门部胆管癌的比较。
Surg Endosc. 2020 Oct;34(10):4382-4387. doi: 10.1007/s00464-019-07211-0. Epub 2019 Oct 29.
4
Current status of laparoscopic radical hilar cholangiocarcinoma in Mainland China.中国大陆腹腔镜根治性肝门胆管癌的现状。
Biosci Trends. 2020 Jul 17;14(3):168-173. doi: 10.5582/bst.2020.03010. Epub 2020 May 9.
5
Minimally invasive surgery for hilar cholangiocarcinoma: a multicenter retrospective analysis of 158 patients.肝门部胆管癌的微创手术:158例患者的多中心回顾性分析
Surg Endosc. 2021 Dec;35(12):6612-6622. doi: 10.1007/s00464-020-08161-8. Epub 2020 Nov 30.
6
Evaluation of the outcomes of biliary-enteric reconstruction in robotic radical resection of hilar cholangiocarcinoma: a single-center propensity score matching analysis.机器人辅助肝门部胆管癌根治术中胆肠重建效果的评估:单中心倾向评分匹配分析。
Sci Rep. 2024 Jun 27;14(1):14836. doi: 10.1038/s41598-024-65875-8.
7
The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma.术中再次切除阳性胆管切缘对肝门部胆管癌临床结局的影响。
Ann Surg Oncol. 2018 May;25(5):1140-1149. doi: 10.1245/s10434-018-6382-0. Epub 2018 Feb 22.
8
Minimally invasive surgery for hilar cholangiocarcinoma: state of art and future perspectives.肝门部胆管癌的微创手术:现状与未来展望
ANZ J Surg. 2019 May;89(5):476-480. doi: 10.1111/ans.14765. Epub 2018 Aug 22.
9
Mini-invasive open resection of colorectal cancer and liver metastases: A meta-analysis.结直肠癌肝转移的微创开腹切除术:一项荟萃分析。
World J Gastroenterol. 2019 Jun 14;25(22):2819-2832. doi: 10.3748/wjg.v25.i22.2819.
10
Minimal Invasive Surgery Instrumented Fusion versus Conventional Open Surgical Instrumented Fusion for the Treatment of Spinal Metastases: A Systematic Review and Meta-analysis.微创外科器械辅助融合术与传统开放手术器械辅助融合术治疗脊柱转移瘤的系统评价和荟萃分析
World Neurosurg. 2021 Apr;148:e264-e274. doi: 10.1016/j.wneu.2020.12.130. Epub 2021 Jan 5.

引用本文的文献

1
Minimally invasive liver surgery for perihilar and intrahepatic cholangiocarcinoma: systematic review and meta-analysis of comparative studies.肝门部及肝内胆管癌的微创肝脏手术:比较研究的系统评价与荟萃分析
Surg Endosc. 2025 Sep 10. doi: 10.1007/s00464-025-11900-4.
2
Green surgery: a systematic review of the environmental impact of laparotomy, laparoscopy, and robotics.绿色手术:剖腹术、腹腔镜检查和机器人手术对环境影响的系统评价
Updates Surg. 2025 May 21. doi: 10.1007/s13304-025-02221-1.
3
Introduction of day-case robotic liver surgery: a case series from a tertiary hepatobiliary and pancreatic centre.

本文引用的文献

1
Perihilar cholangiocarcinoma: are we ready to step towards minimally invasiveness?肝门部胆管癌:我们准备好迈向微创治疗了吗?
Updates Surg. 2020 Jun;72(2):423-433. doi: 10.1007/s13304-020-00752-3. Epub 2020 Mar 27.
2
[Robotic hilar cholangiocarcinoma radical resection compared with laparotomy in prognosis].机器人肝门部胆管癌根治性切除术与开腹手术预后的比较
Zhonghua Wai Ke Za Zhi. 2020 Mar 1;58(3):230-234. doi: 10.3760/cma.j.issn.0529-5815.2020.03.012.
3
Laparoscopic resection for Bismuth type III and IV hilar cholangiocarcinoma: How to improve the radicality without direct palpation.
日间手术机器人肝切除术介绍:来自一家三级肝胆胰中心的病例系列。
Surg Endosc. 2024 Aug;38(8):4329-4335. doi: 10.1007/s00464-024-10913-9. Epub 2024 Jun 14.
4
ASO Author Reflections: Exploring Surgical Approaches to Bismuth Type IIIa Hepatoportal Cholangiocarcinoma.ASO作者反思:探索针对铋IIIa型肝门部胆管癌的手术方法
Ann Surg Oncol. 2024 Oct;31(10):6582-6583. doi: 10.1245/s10434-024-15516-1. Epub 2024 May 25.
5
Research trends in cholangiocarcinoma treatments during the last 3 decades.过去三十年胆管癌治疗的研究趋势。
Heliyon. 2023 Jun 20;9(7):e17100. doi: 10.1016/j.heliyon.2023.e17100. eCollection 2023 Jul.
6
Perihilar-cholangiocarcinoma: what really matters?肝门部胆管癌:真正重要的是什么?
Hepatobiliary Surg Nutr. 2022 Aug;11(4):616-619. doi: 10.21037/hbsn-22-225.
7
Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma.肝门部胆管癌外科治疗的现状
Cancers (Basel). 2022 Apr 28;14(9):2208. doi: 10.3390/cancers14092208.
8
Robotic Surgery for Biliary Tract Cancer.用于胆管癌的机器人手术
Cancers (Basel). 2022 Feb 18;14(4):1046. doi: 10.3390/cancers14041046.
腹腔镜下切除Ⅲ型和Ⅳ型肝门部胆管癌:如何在不直接触诊的情况下提高根治性。
J Surg Oncol. 2019 Dec;120(8):1379-1385. doi: 10.1002/jso.25739. Epub 2019 Nov 5.
4
Total laparoscopic versus open radical resection for hilar cholangiocarcinoma.全腹腔镜与开腹根治性切除术治疗肝门部胆管癌的比较。
Surg Endosc. 2020 Oct;34(10):4382-4387. doi: 10.1007/s00464-019-07211-0. Epub 2019 Oct 29.
5
Minimally invasive surgery for perihilar cholangiocarcinoma: a systematic review.肝门部胆管癌的微创外科治疗:系统评价。
J Robot Surg. 2019 Dec;13(6):717-727. doi: 10.1007/s11701-019-00964-9. Epub 2019 May 2.
6
Robotic liver resection for hepatocellular carcinoma: A systematic review.机器人肝切除术治疗肝细胞癌:系统评价。
Int J Med Robot. 2019 Aug;15(4):e2004. doi: 10.1002/rcs.2004. Epub 2019 May 28.
7
Short- and Long-term Outcomes after Robotic and Laparoscopic Liver Resection for Malignancies: A Propensity Score-Matched Study.机器人和腹腔镜肝切除术治疗恶性肿瘤的短期和长期结果:倾向评分匹配研究。
World J Surg. 2019 Jun;43(6):1594-1603. doi: 10.1007/s00268-019-04927-x.
8
The learning curve for a surgeon in robot-assisted laparoscopic pancreaticoduodenectomy: a retrospective study in a high-volume pancreatic center.机器人辅助腹腔镜胰十二指肠切除术外科医生的学习曲线:在高容量胰腺中心的回顾性研究。
Surg Endosc. 2019 Sep;33(9):2927-2933. doi: 10.1007/s00464-018-6595-0. Epub 2018 Nov 27.
9
Minimally invasive surgery for hilar cholangiocarcinoma: state of art and future perspectives.肝门部胆管癌的微创手术:现状与未来展望
ANZ J Surg. 2019 May;89(5):476-480. doi: 10.1111/ans.14765. Epub 2018 Aug 22.
10
Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial.腹腔镜与开腹结直肠肝转移灶切除术的比较:OSLO-COMET 随机对照试验。
Ann Surg. 2018 Feb;267(2):199-207. doi: 10.1097/SLA.0000000000002353.